ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

KNSA vs UNH // GROSS PROFIT MARGIN

Kiniksa Pharmaceuticals International plc (Class A) (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: KNSA 7 — UNH 7
▲ GROSS PROFIT MARGIN LEADER: UNH
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KNSA VS. UNH) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC KNSA UNH SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin ACTIVE 88.50% 88.57% -0.07 UNH /gross-margins <GO>
Return on Invested Capital (ROIC) 9.90% 11.47% -1.57 UNH /roic <GO>
EV/EBITDA & P/E Valuation 95.0x 16.5x +78.52 UNH /valuation <GO>
Free Cash Flow Yield 1.78% 6.47% -4.69 UNH /fcf-yield <GO>
Operating Margin 11.40% 4.82% +6.58 KNSA /operating-margins <GO>
Net Profit Margin 8.70% 3.14% +5.56 KNSA /net-margins <GO>
Revenue Growth (YoY) 60.10% 6.46% +53.64 KNSA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.32% -2.32 UNH /dividend-safety <GO>
Altman Z-Score & Debt/Equity 24.45 3.12 +21.33 KNSA /balance-sheet <GO>
Piotroski F-Score Quality 9/9 7/9 +2.00 KNSA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — 7.11% — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 59.2 57.4 +1.80 KNSA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.11 0.33 +0.78 KNSA /macro-sensitivity <GO>
Forward P/E Multiple 109.1x 17.7x +91.36 UNH /forward-pe <GO>
Enterprise Scale & Market Cap $7.25B $365.29B -$358.05B UNH /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR KNSA REV UNH REV KNSA GROSS % UNH GROSS % KNSA FCF UNH FCF
FY 2025 $677.6M $447.57B 88.5% 88.7% $136.4M $16.07B
FY 2024 $423.2M $400.28B 85.6% 88.3% $25.4M $20.70B
FY 2023 $270.3M $371.62B — 89.6% $1.1M $25.68B
FY 2022 — $324.16B — 89.6% — $23.40B
FY 2021 — $287.60B — 89.2% — $19.89B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KNSA // BETA 1.11
UNH // BETA 0.33